The incorporation of innovative glucose-lowering medications, such as GLP-1 receptor agonists and SGLT2 inhibitors, represents a promising advancement in the management of T2DM among women of childbearing age. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.